- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02483260
Intravenous Ribavirin Protocol to Treat Individuals With Viral Hemorrhagic Fever
April 3, 2022 updated by: U.S. Army Medical Research and Development Command
Intravenous Ribavirin Protocol to Treat Individuals With Viral Hemorrhagic Fever (Crimean-Congo Hemorrhagic Fever or Lassa Fever)
To provide an intravenous ribavirin therapeutic option for patients with a probable or suspected case of viral hemorrhagic fever, specifically Crimean-Congo hemorrhagic fever or Lassa fever.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: LTC Kristen Bauer, MD
- Phone Number: 314-590-5827
Study Locations
-
-
APO Ae
-
Landstuhl, APO Ae, Germany, 09180
- Recruiting
- Landstuhl Regional Medical Center
-
Contact:
- Maj. Charla Geist
-
Principal Investigator:
- Maj. Charla Geist
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Meets the case definition for a probable or a suspected case of CCHF or LF
- Must be DoD-affiliated personnel including active and reserve component service members, US civilian employees, contractors, other US personnel, and dependents as well as allied military forces and local nationals who have been granted access to the medical facility
- Is at least 18 years of age (17, if active military) and not greater than 65 years of age
- Has a blood sample drawn and a type and cross-match ordered for transfusion
- Has a hemoglobin greater than or equal to10 g/dL before starting IV ribavirin
- Agrees to collection of required specimens
- Agrees to report any adverse events for the duration of the protocol
- Agrees to a follow-up visit and to donate blood and urine specimens at Day 14 (±2 days) after the first dose of IV ribavirin and agrees to all follow-up visits for anemia or other medical conditions as required by the attending physician
- Female patient of childbearing potential must have a pregnancy test. Patient will be counseled concerning the risks of IV ribavirin versus no treatment if the pregnancy test is positive. If the test is negative, patient agrees to take precautions to avoid pregnancy during treatment and for 7 months after treatment.
- Male patient agrees not to have intercourse with a pregnant woman and to take precautions to avoid producing pregnancies during treatment and for 7 months after ribavirin treatment.
- Female patient agrees not to breastfeed during treatment and for 7 months after ribavirin treatment
Exclusion Criteria:
• Has known intolerance to ribavirin.
- Is irreversibly ill on presentation, as defined by presence of profound shock (shock which does not respond to supportive therapy within 3 hours after admission).
- Has hemoglobin less than 10 g/dL that cannot be corrected to 10 g/dL before initiation of IV ribavirin
- Has history of hemoglobinopathies (ie, sickle-cell anemia or thalassemia major).
- Has history of autoimmune hepatitis.
- Has serum calculated creatinine clearance of < 30 mL/min.
- History of second or third degree heart block or sick sinus syndrome without a pacemaker and no capability of a pacemaker placement or Wolfe-Parkinson-White Syndrome.
- A sinus bradycardia of less than 40 beats per minute (see below).
- Is currently being treated with didanosine (ddI). ddI must be discontinued before starting IV ribavirin.
Relative Exclusion Criteria: At the principal investigator's (PI) discretion, an individual may be treated with IV ribavirin, with caution, if one or more of these criteria are present.
- A positive pregnancy test. The patient will be informed of the risk and benefit of treatment with IV ribavirin versus no ribavirin treatment for CCHF (generally associated with high mortality) and severe cases of Lassa fever (high mortality rates) versus mild cases of Lassa fever (low mortality rates).
- A New York Heart Association cardiac functional capacity of Class II or greater for atherosclerotic heart disease (ASHD) and congestive heart failure (CHF).
- Known cardiac defects that may predispose the subject to bradyarrhythmias, such as second or third degree heart block or sick sinus syndrome without a pacemaker, but capability of pacemaker placement, if needed.
- Sinus bradycardia of 41-49 beats per minutes, if the individual is not known to have a low resting heart rate related to physical conditioning.
- Use of drugs known to result in bradyarrhythmias (certain beta blockers and calcium channel blockers, digoxin, as well as clonidine, cholinesterase inhibitors, and lithium).
- History of gout
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: 10-day course of treatment
10-day course of treatment with follow-up 14 ± 2 days after first dose
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Adverse reactions
Time Frame: 5 years
|
5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: LTC Kristen Bauer, MD, Landstahl Regional Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
June 16, 2016
Primary Completion (ANTICIPATED)
October 1, 2022
Study Completion (ANTICIPATED)
December 1, 2022
Study Registration Dates
First Submitted
June 24, 2015
First Submitted That Met QC Criteria
June 24, 2015
First Posted (ESTIMATE)
June 26, 2015
Study Record Updates
Last Update Posted (ACTUAL)
April 5, 2022
Last Update Submitted That Met QC Criteria
April 3, 2022
Last Verified
April 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- S-13-08
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Viral Hemorrhagic Fever
-
Sarepta Therapeutics, Inc.United States Department of DefenseWithdrawnEbola Hemorrhagic FeverUnited States
-
Sarepta Therapeutics, Inc.United States Department of DefenseCompletedEbola Hemorrhagic FeverUnited States
-
Gamaleya Research Institute of Epidemiology and...CompletedEbola Hemorrhagic FeverRussian Federation
-
The Scientific and Technological Research Council...MonitorCROCompleted
-
Tongji HospitalRecruitingHFRS (Hemorrhagic Fever With Renal Syndrome)China
-
Sanofi Pasteur, a Sanofi CompanyUnited States Department of DefenseCompletedDengue | Dengue Fever | Dengue Hemorrhagic FeverUnited States
-
National Institute of Allergy and Infectious Diseases...The Emmes Company, LLC; US Military HIV Research ProgramCompletedHemorrhagic Fever, EbolaUganda
-
Universitätsklinikum Hamburg-EppendorfUniversity Hospital, Geneva; Wellcome Trust; KEMRI-Wellcome Trust Collaborative... and other collaboratorsCompletedHemorrhagic Fever, EbolaGermany
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic FeverSingapore
-
Janssen Vaccines & Prevention B.V.Bavarian Nordic GmbHTerminatedHemorrhagic Fever, EbolaFrance, United Kingdom, Kenya, United States, Uganda, Burkina Faso, Tanzania
Clinical Trials on Ribavirin
-
Institute of Liver and Biliary Sciences, IndiaTerminated
-
University of Roma La SapienzaCompleted
-
Tel-Aviv Sourasky Medical CenterUnknown
-
Hoffmann-La RocheCompletedHealthy VolunteerMexico
-
University of BernRoche Pharma AG; University of Lausanne; University of Basel; Cantonal Hospital... and other collaboratorsCompleted
-
Janssen-Cilag International NVNo longer availableHepatitis CAustralia, Belgium, Germany, Spain, Switzerland, Romania, Serbia, Greece, New Zealand, Brazil, Russian Federation, Austria, Hungary, Czech Republic, Luxembourg
-
Conatus Pharmaceuticals Inc.Completed
-
National Institute of Diabetes and Digestive and...CompletedHepatitis C, ChronicUnited States
-
Memorial Sloan Kettering Cancer CenterCompletedHEAD & NECK CancerUnited States
-
Kaohsiung Medical University Chung-Ho Memorial...Completed